Several immune checkpoint pathways, such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and macrophage checkpoint CD47, can play an important role in the treatment of AML or MDS. Here, PDCD1 is linked to acute myeloid leukemia.